Leukemia
Conditions
Keywords
chronic phase chronic myelogenous leukemia, chronic myelogenous leukemia, BCR-ABL1 positive
Brief summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate and chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate plus cytarabine in treating patients who have newly diagnosed chronic myeloid leukemia.
Detailed description
OBJECTIVES: * Determine the maximum tolerated dose of imatinib mesylate and cytarabine in patients with newly diagnosed chronic phase chronic myeloid leukemia. * Determine the feasibility of this regimen as defined by dose-limiting toxicity of this regimen and treatment-related mortality in no more than 5% of these patients. * Determine the rate and duration of molecular response, complete hematological response, and complete cytogenetic response in patients treated with this regimen. * Determine the time to treatment failure of patients treated with this regimen. * Determine the overall survival of patients treated with this regimen. OUTLINE: This is a multicenter, dose-escalation study of imatinib mesylate and cytarabine. Patients receive oral imatinib mesylate alone once daily on days 1-21. Patients then receive oral imatinib mesylate once daily and cytarabine IV over 1-3 hours on days 1-7. Combination therapy repeats every 28-42 days for 2 courses. Patients then receive maintenance oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 5-20 patients receive escalating doses of imatinib mesylate and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 5/5, 5/10, or 5/20 patients experience dose-limiting toxicity. Patients are followed every 6 months. PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study within 2 years.
Interventions
DRUGcytarabine
DRUGimatinib mesylate
Sponsors
Commissie Voor Klinisch Toegepast Onderzoek
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Newly diagnosed chronic myeloid leukemia in first chronic phase (within the past 6 months) * Philadelphia-chromosome positive OR * bcr-abl rearrangement * No prior treatment within the past 6 months other than hydroxyurea PATIENT CHARACTERISTICS: Age: * 18 to 65 Performance status: * WHO 0-2 Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * No hepatic dysfunction * Bilirubin less than 2 times normal * ALT less than 4 times normal Renal: * No renal dysfunction * Creatinine less than 2.3 mg/dL Cardiovascular: * No severe cardiac dysfunction * No New York Heart Association class II-IV heart disease Pulmonary: * No severe pulmonary disease Other: * HIV negative * No severe neurologic disease * No active uncontrolled infection * No other active malignancy within the past 5 years except basal cell skin cancer or stage 0 cervical cancer * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * See Disease Characteristics * No concurrent allogeneic transplantation with an HLA-A, B, DR-matched sibling donor or matched-unrelated donor Chemotherapy: * See Disease Characteristics Endocrine therapy: * See Disease Characteristics Radiotherapy: * See Disease Characteristics Surgery: * See Disease Characteristics Other: * No concurrent grapefruit or grapefruit juice
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose-limiting toxicity and treatment-related toxicity per dose level | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to treatment failure | — |
| Overall survival | — |
| Rate and duration of complete cytogenetic response | — |
| Rate and duration of molecular response | — |
| Rate and duration of complete hematological response | — |
Countries
Belgium, Netherlands
Outcome results
None listed